Acrodermatitis chronica atrophicans

L12_ACRODERMATITIS

acrodermatitis chronica atrophicans: An acrodermatitis characterized by a chronically progressive course, leading to widespread atrophy of the skin. It is a clinical manifestation of Lyme borreliosis.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519972
1. Apply sex-specific rule None	519972
2. Check conditions None	519972
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — L90.4 Hospital discharge: ICD-9 — 7018C Hospital discharge: ICD-8 — 70190 Cause of death: ICD-10 — L90.4 Cause of death: ICD-9 — 7018C Cause of death: ICD-8 — 70190 2 out of 7 registries used, show all original rules.	54
4. Check minimum number of events None	54
5. Include endpoints None	54
6. Filter based on genotype QC (FinnGen only)	53

Control definitions (FinnGen only)

Control exclude: L12_OTHERSKINSUBCUTIS

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: L90
Name in latin: Acrodermatitis chronica atrophicans

NAME	L12_ACRODERMATITIS
CONTROL_EXCLUDE	L12_OTHERSKINSUBCUTIS
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	L904
HD_ICD_9	7018C
HD_ICD_8	70190
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	L904
COD_ICD_9	7018C
COD_ICD_8	70190
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Acrodermatitis chronica atrophicans based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	334	248	84
Only index persons	309	234	75
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.00
Only index persons	0.01	0.01	0.00
Median age at first event (years)
Whole population	62.27	64.11	57.42
Only index persons	62.64	64.30	57.46

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	53	34	19
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	64.63	64.50	64.86

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
54: Matched controls
540

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

L90.4

ICD-10 Finland

Acrodermatitis chronica atrophicans

10243.9

72.9

L90.0

ICD-10 Finland

Lichen sclerosus et atrophicus

37.7

9.9

TQX10

NOMESCO Finland

Biopsy of skin and subcutaneous tissue

13.2

9.7

A69.2

ICD-10 Finland

Lyme disease

13.7

9.3

LFB00

NOMESCO Finland

Biopsy of vulva or perineum

35.2

7.4

L30.9

ICD-10 Finland

Dermatitis, unspecified

4.6

6.1

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3037522) Nuclear Ab [Titer] in Serum

4.24

5.35

1.3

496.00

760.00

titre

—

(40768443) Skin Pathology biopsy report

8.32

5.26

1.3

1.2

—

(3000620) Complement C3 [Mass/volume] in Serum or Plasma

8.73

4.56

1.1

1.2

1.23

1.10

g/l

—

(3017766) Complement C4 [Mass/volume] in Serum or Plasma

8.73

4.56

1.1

1.2

0.27

0.21

g/l

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

7.01

3.65

1.5

1.2

—

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

2.90

3.24

1.5

1.3

35.54

39.41

iu/ml

—

(40760892) CBC W Ordered Manual Differential panel - Blood

210

2.67

2.99

7.2

5.8

—

(3039162) Centromere protein B Ab [Units/volume] in Serum

7.72

2.60

1.4

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

6.74

2.42

1.0

1.3

—

(3013707) Erythrocyte sedimentation rate by Westergren method

344

2.84

2.40

5.4

4.5

12.41

11.28

mm/h

0.21

308

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

5.04

2.34

1.3

1.6

—

(3009445) Proteinase 3 Ab [Units/volume] in Serum

4.07

2.23

1.1

1.2

—

(3015736) pH of Urine

183

2.26

2.22

3.6

3.4

—

5.68

—

(3014111) Lactate [Moles/volume] in Serum or Plasma

3.17

2.12

9.8

6.3

1.19

1.61

mmol/l

—

(40768804) Tissue Pathology biopsy report

188

2.17

2.03

2.6

1.9

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

4.08

1.99

12.8

6.5

26.50

25.17

mmol/l

—

(3037467) Urinalysis macro (dipstick) panel - Urine

320

2.41

1.92

5.1

4.0

—

(3000991) Gas panel - Venous blood

2.88

1.90

16.7

6.3

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

2.32

1.89

1.4

1.2

1.36

16.39

u/ml

—

(3000330) Specific gravity of Urine by Test strip

3.34

1.87

2.7

3.3

—

(3014218) Bicarbonate [Moles/volume] standard in Arterial blood

3.42

1.71

9.5

9.3

24.67

25.42

mmol/l

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

2.27

1.67

1.7

2.0

—

(3021589) Normoblasts [#/volume] in Blood

203

1.93

1.52

8.1

7.8

0.00

e9/l

0.50

166

(40758558) Short blood count panel - Blood

118

1.94

1.39

10.4

8.1

—

(3000494) Fungus identified in Specimen by Culture

2.26

1.39

1.7

1.6

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

2.68

1.34

2.3

1.3

—

(3045414) Leukocytes [Presence] in Urine

2.95

1.31

2.0

1.4

—

(3012095) Magnesium [Moles/volume] in Serum or Plasma

2.06

1.29

2.5

3.0

0.78

0.82

mmol/l

0.54

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

2.79

1.24

6.4

2.5

0.80

0.71

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

2.79

1.24

8.2

6.8

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

2.79

1.24

6.4

2.5

0.96

1.12

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

2.18

1.20

2.3

5.30

7.45

umol/l

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

0.00

1.20

0.0

1.8

—

(3002256) Pathology report gross observation

2.20

1.12

1.3

1.1

—

(3027945) Reticulocytes/100 erythrocytes in Blood

2.09

1.10

1.9

3.5

1.78

1.64

—

(3022217) INR in Platelet poor plasma by Coagulation assay

201

1.69

1.04

13.7

15.3

1.10

1.28

inr

—

(3003458) Phosphate [Moles/volume] in Serum or Plasma

1.92

1.00

8.2

3.0

1.06

1.08

mmol/l

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

1.92

1.00

11.0

5.9

105.67

104.75

mmol/l

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

0.00

1.00

0.0

7.8

—

24.53

—

(3026008) Bacteria identified in Urine by Culture

149

1.67

0.95

2.7

2.9

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

0.00

0.81

0.0

1.7

—

(36304419) Bacteria [Presence] in Urine

137

1.60

0.79

3.1

2.5

—

(3018095) Leukocytes [#/volume] in Urine

174

1.56

0.79

3.7

3.4

12.19

46.21

e6/l

1.56

122

(3014007) Fractional oxyhemoglobin in Arterial blood

1.94

0.70

8.8

9.0

94.00

93.77

—

(36660697) Celiac disease serology panel - Serum

1.68

0.68

1.1

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

1.86

0.68

1.4

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.80

0.65

1.0

1.2

—

(3022145) Colonoscopy Study observation

1.63

0.63

1.9

1.3

—

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

1.73

0.63

8.8

8.3

1.28

1.52

—

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

1.73

0.63

8.8

8.2

0.40

0.75

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

108

1.54

0.62

4.5

3.3

—

(3043409) Potassium [Moles/volume] in Arterial blood

0.00

0.61

0.0

4.3

—

3.79

—

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.61

0.0

3.9

—

1.36

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.70

0.58

1.7

2.8

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

184

1.44

0.57

2.2

2.0

111.00

93.24

pmol/l

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

253

1.42

0.55

8.9

6.2

12.27

10.97

umol/l

0.45

239

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

176

1.42

0.54

3.8

2.9

—

(3019832) Treponema pallidum Ab [Presence] in Serum

1.56

0.53

1.3

1.9

—

(3012544) pH of Venous blood

1.56

0.53

17.5

2.2

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.60

0.51

1.9

1.7

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

460

1.70

0.50

20.8

13.3

20.53

21.70

mg/l

0.07

342

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.55

0.48

3.7

7.6

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

1.47

0.47

2.5

2.4

0.64

1.04

e6/l

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

142

1.40

0.47

4.0

2.2

75.78

58.55

u/l

0.51

131

(3002179) Metamyelocytes/100 leukocytes in Blood

1.57

0.42

1.4

3.9

—

1.18

—

(3034770) Mitochondria Ab [Titer] in Serum

0.00

0.42

0.0

1.1

—

(3025159) Blasts/100 leukocytes in Blood

1.47

0.40

1.4

4.0

—

0.10

—

(3021440) Promyelocytes/100 leukocytes in Blood

1.43

0.39

1.4

4.1

—

0.00

—

(4035726) Immunohistochemistry procedure

1.52

0.37

1.0

1.2

—

(3002173) Hemoglobin [Mass/volume] in Arterial blood

1.52

0.37

9.3

7.6

112.00

121.93

g/l

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.52

0.37

4.2

1.3

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

443

1.47

0.34

19.1

12.7

77.93

80.13

ml/min/173m2

0.34

359

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.34

0.34

1.8

1.7

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

1.39

0.33

2.6

2.8

6.80

4.01

e6/l

—

(1761868) Lipid panel - Serum or Plasma

150

0.74

0.32

4.0

3.2

—

(3007164) IgA [Mass/volume] in Serum or Plasma

103

1.35

0.32

1.1

1.4

6.31

2.53

g/l

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

119

0.71

0.31

4.6

5.4

2.07

2.35

ug/l

—

103

(3041096) Erythrocytes [Presence] in Urine by Automated

122

1.32

0.31

3.3

3.6

—

(3042936) Bacteria identified in Isolate by Culture

1.36

0.30

1.9

2.0

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.32

0.29

1.5

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

173

1.25

0.26

2.4

4.2

27.73

24.59

ng/l

0.07

124

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.35

0.24

2.8

2.2

—

(3017181) Myelocytes/100 leukocytes in Blood

1.31

0.23

1.4

3.8

—

0.79

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

176

1.22

0.21

4.3

3.9

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.21

0.0

3.5

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.6

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.21

0.0

3.6

—

146.45

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

3.5

—

79.41

—

(3047181) Lactate [Moles/volume] in Blood

0.00

0.21

0.0

7.0

—

1.00

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.21

0.0

1.2

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.21

0.0

3.7

—

(3003396) Base excess in Arterial blood by calculation

1.31

0.21

9.2

7.1

0.50

1.85

mmol/l

—

(3027801) Oxygen [Partial pressure] in Arterial blood

1.31

0.21

9.3

7.1

11.88

11.37

kpa

—

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

1.31

0.21

9.5

7.1

5.32

5.00

kpa

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3050449) Albumin [Mass/time] in Urine collected for unspecified duration

0.00

0.21

0.0

3.0

—

82.63

—

(3027008) Opiates [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3016879) Cocaine [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.1

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

0.00

0.20

0.0

1.7

—

132.38

—

(4034850) Laboratory test

0.00

0.20

0.0

7.1

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.23

0.18

2.0

1.7

—

(3003694) ABO and Rh group [Type] in Blood

128

0.82

0.15

1.5

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

104

1.20

0.14

2.3

1.9

—

(40761535) Cells panel - Urine sediment

1.15

0.10

5.6

4.0

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.10

0.10

2.8

2.4

—

(4200892) Spirometry reversibility

1.07

0.10

1.2

1.3

—

(3019225) pH of Specimen

1.05

0.09

3.6

4.6

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

214

0.90

0.09

2.7

2.3

—

(40768797) Stomach Pathology biopsy report

0.85

0.08

1.2

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

466

0.91

0.08

5.2

5.3

2.86

2.70

mmol/l

0.57

431

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

0.86

0.07

1.7

1.4

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

455

0.93

0.07

4.9

4.7

1.56

1.51

mmol/l

0.28

418

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

370

1.09

0.05

13.4

7.5

76.74

79.81

u/l

0.18

338

(3023368) Bacteria identified in Blood by Culture

114

1.07

0.01

3.7

3.8

—

(3013512) EKG study

146

0.94

0.01

3.6

4.1

—

(3044889) 12 lead EKG panel

319

1.01

0.00

3.8

3.9

—

(3044640) Blood type and Crossmatch panel - Blood

135

1.05

0.00

2.6

1.9

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

255

0.96

0.00

3.2

2.6

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

0.00

0.0

1.3

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.6

—

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

444

1.08

0.00

4.4

4.1

1.11

1.27

mmol/l

1.01

405

(3023419) Bacteria identified in Sputum by Culture

0.00

0.0

4.4

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

0.88

-0.00

4.2

1.8

2.48

2.45

g/l

—

(3024172) Erythropoietin (EPO) [Units/volume] in Serum or Plasma

0.00

-0.00

0.0

1.1

—

16.50

—

(3045142) Bone marrow Pathology biopsy report

0.00

-0.00

0.0

1.0

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

0.00

-0.00

0.0

1.0

—

(3026179) Normetanephrine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

0.40

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

-0.00

0.0

1.3

—

(3021901) Oxygen saturation in Capillary blood

0.00

-0.00

0.0

1.5

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.1

—

108.43

—

(3039000) Anion gap in Blood

0.00

-0.00

0.0

6.7

—

10.00

—

(36032269) Testosterone Free [Moles/volume] in Serum or Plasma by calculation

0.00

-0.00

0.0

1.8

—

162.00

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

-0.00

0.0

1.3

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

(3041642) Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.1

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

-0.00

0.0

1.0

—

(3020717) Zinc [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

12.22

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

-0.00

0.0

1.4

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

(3005570) Glucose [Moles/volume] in Urine

0.00

-0.00

0.0

2.5

—

(3011288) Drugs identified in Urine by Screen method

0.00

-0.00

0.0

1.1

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.0

—

(3044927) Protein electrophoresis panel - Urine

0.00

-0.00

0.0

1.0

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

-0.00

0.0

1.5

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

0.00

-0.00

0.0

1.5

—

(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay

0.00

-0.00

0.0

3.2

—

106.60

—

(21494434) Karyotype in Bone marrow

0.00

-0.00

0.0

1.0

—

(3014702) Chromogranin A [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.2

—

3.64

—

(3038546) Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(3051593) INR in Capillary blood by Coagulation assay

0.00

-0.00

0.0

11.0

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

0.00

-0.00

0.0

4.2

—

(3040359) Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.1

—

3.91

—

(3028167) CD3+CD4+ (T4 helper) cells [#/volume] in Blood

0.00

-0.00

0.0

1.6

—

336.80

—

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

440

1.00

-0.00

6.1

6.2

38.00

39.93

mmol/mol

1.13

411

(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.0

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

0.00

-0.00

0.0

4.0

—

(4281824) Cell count and differential, peritoneal fluid

0.00

-0.00

0.0

1.0

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

-0.00

0.0

1.6

—

(3018572) Chloride [Moles/volume] in Blood

0.00

-0.00

0.0

6.7

—

104.00

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

-0.00

0.0

1.0

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.00

-0.00

1.6

1.3

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

0.00

-0.00

0.0

1.0

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.7

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.88

-0.00

1.6

1.2

—

(40761511) CBC panel - Blood by Automated count

484

1.13

-0.00

14.8

12.3

—

(3022948) Iron [Moles/volume] in Serum or Plasma

0.94

-0.00

3.7

1.8

15.23

14.02

umol/l

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

457

1.04

-0.00

4.8

4.7

4.77

4.65

mmol/l

0.34

424

Mortality – FinRegistry

↥

Association

Association between endpoint L12_ACRODERMATITIS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_ACRODERMATITIS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: L12_ACRODERMATITIS – Acrodermatitis chronica atrophicans

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Acrodermatitis chronica atrophicans

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints